Ubs Asset Management Americas Inc Moon Lake Immunotherapeutics Transaction History
Ubs Asset Management Americas Inc
- $381 Billion
- Q3 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 35,814 shares of MLTX stock, worth $1.95 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35,814
Previous 18,234
96.41%
Holding current value
$1.95 Million
Previous $801,000
125.34%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding MLTX
# of Institutions
124Shares Held
58.2MCall Options Held
52.2KPut Options Held
38K-
Bvf Inc San Francisco, CA21.8MShares$1.18 Billion34.86% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$462 Million30.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.98MShares$162 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$151 Million2.1% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.32MShares$126 Million0.02% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $2.01B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...